These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Li L; Wang L; Zhang W; Tang B; Zhang J; Song H; Yao D; Tang Y; Chen X; Yang Z; Wang G; Li X; Zhao J; Ding H; Reed E; Li QQ Anticancer Res; 2004; 24(3b):1973-9. PubMed ID: 15274387 [TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991 [TBL] [Abstract][Full Text] [Related]
7. [Lysophosphatidic acid in ovarian cancer patients]. Sedlákova I; Vávrová J; Tosner J; Hanousek L Ceska Gynekol; 2006 Jul; 71(4):312-7. PubMed ID: 16956044 [TBL] [Abstract][Full Text] [Related]
8. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Chen CA; Cheng WF; Lee CN; Chen TM; Kung CC; Hsieh FJ; Hsieh CY Gynecol Oncol; 1999 Aug; 74(2):235-40. PubMed ID: 10419737 [TBL] [Abstract][Full Text] [Related]
15. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. Alvarez Secord A; Sayer R; Snyder SA; Broadwater G; Rodriguez GC; Berchuck A; Blackwell K Gynecol Oncol; 2004 Jul; 94(1):74-9. PubMed ID: 15262122 [TBL] [Abstract][Full Text] [Related]
16. Changes in tumor markers, coagulation function and serum VEGF in patients with ovarian cancer and benign ovarian disease. Wang J; Zhu M; Zhou X; Wang T; Zhang J J BUON; 2020; 25(5):2287-2292. PubMed ID: 33277847 [TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors]. Peng XP; Li JD; Li MD; Ye XM; Yan WC Ai Zheng; 2002 Feb; 21(2):181-5. PubMed ID: 12479072 [TBL] [Abstract][Full Text] [Related]
18. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. Stadlmann S; Amberger A; Pollheimer J; Gastl G; Offner FA; Margreiter R; Zeimet AG Gynecol Oncol; 2005 Jun; 97(3):784-9. PubMed ID: 15943987 [TBL] [Abstract][Full Text] [Related]
19. Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. Santin AD; Bellone S; Ravaggi A; Roman J; Smith CV; Pecorelli S; Cannon MJ; Parham GP BJOG; 2001 Aug; 108(8):804-8. PubMed ID: 11510703 [TBL] [Abstract][Full Text] [Related]
20. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Gadducci A; Ferdeghini M; Fanucchi A; Annicchiarico C; Ciampi B; Prontera C; Genazzani AR Anticancer Res; 1999; 19(2B):1401-5. PubMed ID: 10365113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]